Update Breast Cancer 2023 Part 1 - Early Stage Breast Cancer

Andreas D. Hartkopf; Tanja N. Fehm; Manfred Welslau; Volkmar Müller; Florian Schütz; Peter A. Fasching; Wolfgang Janni; Isabell Witzel; Christoph Thomssen; Milena Beierlein; Erik Belleville; Michael Untch; Marc Thill; Hans Tesch; Nina Ditsch; Michael P. Lux; Bahriye Aktas; Maggie Banys-Paluchowski; Cornelia Kolberg-Liedtke; Achim Wöckel; Hans Christian Kolberg; Nadia Harbeck; Elmar Stickeler; Rupert Bartsch; Andreas Schneeweiss; Johannes Ettl; Rachel Würstlein; David Krug; Florin Andrei Taran; Diana Lüftner

doi:10.1055/a-2074-0551

Update Breast Cancer 2023 Part 1 - Early Stage Breast Cancer

Andreas D. Hartkopf, Tanja N. Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter A. Fasching^*, Wolfgang Janni, Isabell Witzel, Christoph Thomssen, Milena Beierlein, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P. Lux, Bahriye Aktas, Maggie Banys-Paluchowski, Cornelia Kolberg-Liedtke, Achim WöckelHans Christian Kolberg, Nadia Harbeck, Elmar Stickeler, Rupert Bartsch, Andreas Schneeweiss, Johannes Ettl, Rachel Würstlein, David Krug, Florin Andrei Taran, Diana Lüftner

^*Korrespondierende/r Autor/-in für diese Arbeit

5 Zitate (Scopus)

Abstract

With abemaciclib (monarchE study) and olaparib (OlympiA study) gaining approval in the adjuvant treatment setting, a significant change in the standard of care for patients with early stage breast cancer has been established for some time now. Accordingly, some diverse developments are slowly being transferred from the metastatic to the adjuvant treatment setting. Recently, there have also been positive reports of the NATALEE study. Other clinical studies are currently investigating substances that are already established in the metastatic setting. These include, for example, the DESTINY Breast05 study with trastuzumab deruxtecan and the SASCIA study with sacituzumab govitecan. In this review paper, we summarize and place in context the latest developments over the past months.

Originalsprache	Englisch
Zeitschrift	Geburtshilfe und Frauenheilkunde
Jahrgang	83
Ausgabenummer	6
Seiten (von - bis)	653-663
Seitenumfang	11
ISSN	0016-5751
DOIs	https://doi.org/10.1055/a-2074-0551
Publikationsstatus	Veröffentlicht - 12.04.2023

Fördermittel

This paper was partly developed as a result of funding from the companies onkowissen.de, Gilead, Lilly, Novartis, Pfizer, and MSD. None of these companies had any part in the preparation of or recommendations made in this manuscript. The authors are solely responsible for the content of the manuscript.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Profilbereich: Lübeck Integrated Oncology Network (LION)
Zentren: Universitäres Cancer Center Schleswig-Holstein (UCCSH)

DFG-Fachsystematik

2.22-21 Gynäkologie und Geburtshilfe
2.22-14 Hämatologie, Onkologie

Dokumente

10.1055/a-2074-0551

Weitere Links

Link to publication in Scopus

Zitieren

Hartkopf, A. D., Fehm, T. N., Welslau, M., Müller, V., Schütz, F., Fasching, P. A., Janni, W., Witzel, I., Thomssen, C., Beierlein, M., Belleville, E., Untch, M., Thill, M., Tesch, H., Ditsch, N., Lux, M. P., Aktas, B., Banys-Paluchowski, M., Kolberg-Liedtke, C., ... Lüftner, D. (2023). Update Breast Cancer 2023 Part 1 - Early Stage Breast Cancer. Geburtshilfe und Frauenheilkunde, 83(6), 653-663. https://doi.org/10.1055/a-2074-0551

@article{92856cd75e2e4c67bff48399933cedde,

title = "Update Breast Cancer 2023 Part 1 - Early Stage Breast Cancer",

abstract = "With abemaciclib (monarchE study) and olaparib (OlympiA study) gaining approval in the adjuvant treatment setting, a significant change in the standard of care for patients with early stage breast cancer has been established for some time now. Accordingly, some diverse developments are slowly being transferred from the metastatic to the adjuvant treatment setting. Recently, there have also been positive reports of the NATALEE study. Other clinical studies are currently investigating substances that are already established in the metastatic setting. These include, for example, the DESTINY Breast05 study with trastuzumab deruxtecan and the SASCIA study with sacituzumab govitecan. In this review paper, we summarize and place in context the latest developments over the past months.",

author = "Hartkopf, \{Andreas D.\} and Fehm, \{Tanja N.\} and Manfred Welslau and Volkmar M{\"u}ller and Florian Sch{\"u}tz and Fasching, \{Peter A.\} and Wolfgang Janni and Isabell Witzel and Christoph Thomssen and Milena Beierlein and Erik Belleville and Michael Untch and Marc Thill and Hans Tesch and Nina Ditsch and Lux, \{Michael P.\} and Bahriye Aktas and Maggie Banys-Paluchowski and Cornelia Kolberg-Liedtke and Achim W{\"o}ckel and Kolberg, \{Hans Christian\} and Nadia Harbeck and Elmar Stickeler and Rupert Bartsch and Andreas Schneeweiss and Johannes Ettl and Rachel W{\"u}rstlein and David Krug and Taran, \{Florin Andrei\} and Diana L{\"u}ftner",

year = "2023",

month = apr,

day = "12",

doi = "10.1055/a-2074-0551",

language = "English",

volume = "83",

pages = "653--663",

journal = "Geburtshilfe und Frauenheilkunde",

issn = "0016-5751",

publisher = "Georg Thieme Verlag",

number = "6",

}

Hartkopf, AD, Fehm, TN, Welslau, M, Müller, V, Schütz, F, Fasching, PA, Janni, W, Witzel, I, Thomssen, C, Beierlein, M, Belleville, E, Untch, M, Thill, M, Tesch, H, Ditsch, N, Lux, MP, Aktas, B, Banys-Paluchowski, M, Kolberg-Liedtke, C, Wöckel, A, Kolberg, HC, Harbeck, N, Stickeler, E, Bartsch, R, Schneeweiss, A, Ettl, J, Würstlein, R, Krug, D, Taran, FA & Lüftner, D 2023, 'Update Breast Cancer 2023 Part 1 - Early Stage Breast Cancer', Geburtshilfe und Frauenheilkunde, Jg. 83, Nr. 6, S. 653-663. https://doi.org/10.1055/a-2074-0551

TY - JOUR

T1 - Update Breast Cancer 2023 Part 1 - Early Stage Breast Cancer

AU - Hartkopf, Andreas D.

AU - Fehm, Tanja N.

AU - Welslau, Manfred

AU - Müller, Volkmar

AU - Schütz, Florian

AU - Fasching, Peter A.

AU - Janni, Wolfgang

AU - Witzel, Isabell

AU - Thomssen, Christoph

AU - Beierlein, Milena

AU - Belleville, Erik

AU - Untch, Michael

AU - Thill, Marc

AU - Tesch, Hans

AU - Ditsch, Nina

AU - Lux, Michael P.

AU - Aktas, Bahriye

AU - Banys-Paluchowski, Maggie

AU - Kolberg-Liedtke, Cornelia

AU - Wöckel, Achim

AU - Kolberg, Hans Christian

AU - Harbeck, Nadia

AU - Stickeler, Elmar

AU - Bartsch, Rupert

AU - Schneeweiss, Andreas

AU - Ettl, Johannes

AU - Würstlein, Rachel

AU - Krug, David

AU - Taran, Florin Andrei

AU - Lüftner, Diana

PY - 2023/4/12

Y1 - 2023/4/12

N2 - With abemaciclib (monarchE study) and olaparib (OlympiA study) gaining approval in the adjuvant treatment setting, a significant change in the standard of care for patients with early stage breast cancer has been established for some time now. Accordingly, some diverse developments are slowly being transferred from the metastatic to the adjuvant treatment setting. Recently, there have also been positive reports of the NATALEE study. Other clinical studies are currently investigating substances that are already established in the metastatic setting. These include, for example, the DESTINY Breast05 study with trastuzumab deruxtecan and the SASCIA study with sacituzumab govitecan. In this review paper, we summarize and place in context the latest developments over the past months.

AB - With abemaciclib (monarchE study) and olaparib (OlympiA study) gaining approval in the adjuvant treatment setting, a significant change in the standard of care for patients with early stage breast cancer has been established for some time now. Accordingly, some diverse developments are slowly being transferred from the metastatic to the adjuvant treatment setting. Recently, there have also been positive reports of the NATALEE study. Other clinical studies are currently investigating substances that are already established in the metastatic setting. These include, for example, the DESTINY Breast05 study with trastuzumab deruxtecan and the SASCIA study with sacituzumab govitecan. In this review paper, we summarize and place in context the latest developments over the past months.

UR - https://www.scopus.com/pages/publications/85161638467

U2 - 10.1055/a-2074-0551

DO - 10.1055/a-2074-0551

M3 - Journal articles

AN - SCOPUS:85161638467

SN - 0016-5751

VL - 83

SP - 653

EP - 663

JO - Geburtshilfe und Frauenheilkunde

JF - Geburtshilfe und Frauenheilkunde

IS - 6

ER -

Update Breast Cancer 2023 Part 1 - Early Stage Breast Cancer

Abstract

Fördermittel

UN SDGs

Strategische Forschungsbereiche und Zentren

DFG-Fachsystematik

Dokumente

Weitere Links

Fingerprint

Zitieren